Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06856278
Starting soon Phase 1/2

Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

NCT06856278 · tracked via the Priya Life Science China tracker
Sponsor
Zhejiang Provincial People's Hospital
Phase
Phase 1/2
Started
2025-02-22
Last updated
2025-03-04

Condition(s) studied

Anaplastic Throid Carcinoma

Investigational drug(s) / intervention(s)

NKG2D CAR-NK with PD-1 Antibody

NKG2D CAR-NK with PD-1 Antibody: Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.

Study summary

The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 18-75 years (including boundary values), male or female. 2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm. 3. Liver and kidney function is good, and can tolerate treatment. 4. Be able to cooperate with the completion of treatment and follow-up work. 5. No other systemic diseases, including other malignancies. Exclusion Criteria: 1. Need to breastfeed the baby or have fertility needs； 2. Immune system diseases; 3. Diseases of the blood system; 4. Mental system diseases; 5. Interstitial pneumonia, lung disease, etc.; 6. Failure to follow rules of this study.

Primary outcome measure(s)

  • Safety and tolerability — From the start of the trial to day 56 after the first infusion of CAR-NK.
    Safety and tolerability at 28 days after combination therapy, dose limiting toxicity (DLT) and maximum tolerated dose (MTD) were determined.

Trial sites (1)

FacilityCityRegionStatus
Zhejiang Provincial People's Hospital Hangzhou Zhejiang

More Zhejiang Provincial People's Hospital trials in China

Xiaojin Pill/Neixiao Luoli Pill for the Treatment of Thyroid Nodules Starting soon
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer Recruiting
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study Recruiting
Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06856278 on ClinicalTrials.gov ↗ ← All trials in China